Study of Oral Anticoagulants to Prevent Stroke in Patients Aged 55 and Older with Recent Stress-Related Atrial Fibrillation Episodes
Led by Population Health Research Institute · Updated on 2026-01-12
2270
Participants Needed
105
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This research aims to compare the effects of oral anticoagulation versus no anticoagulation in patients aged 55 and older who have had recent episodes of transient atrial fibrillation triggered by stress and have additional factors that increase their risk of stroke. The study is a multinational, investigator-initiated, prospective, randomized, open-label trial evaluating the impact of non-vitamin K oral anticoagulants NOACs on preventing stroke and other serious cardiovascular events.
Participants will be randomly assigned to either receive one of several NOACs, such as edoxaban, apixaban, dabigatran, or rivaroxaban, prescribed by their physician for the duration of the follow-up, or to a control group that will not receive anticoagulants unless medically indicated during the study. The choice of specific NOAC and dose adjustments are determined by the prescribing doctor. The study excludes patients with certain conditions like chronic atrial fibrillation, severe kidney or liver disease, recent cardiac surgery, or bleeding risks.
During the study, participants will be monitored for up to 24 months to assess the occurrence of non-hemorrhagic stroke, systemic embolism, vascular mortality, myocardial infarction, peripheral arterial thrombosis, amputation, and venous thromboembolism. Regular follow-up will include evaluation of these outcomes to measure the effectiveness and safety of anticoagulation compared to no anticoagulation. Participants will provide informed consent and remain under medical supervision throughout the trial.
CONDITIONS
Brief Title
Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress
Research Team
C
Cassie McDonald
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Use of a NOAC (edoxaban, apixaban, dabigatran, or rivaroxaban) selected by the physician for patients with recent AFOTS episodes
No anticoagulation provided during follow‑up for eligible patients
Oral anticoagulation is typically initiated based on CHA2DS2‑VASc risk stratification in patients with AF
Role in trial
Investigational treatment assigned to half of participants
Control intervention representing absence of anticoagulation
Represents current risk‑guided practice outside the trial
Primary use
Prevent stroke or systemic embolism following AFOTS episodes
Observation of natural risk without anticoagulation
Standard preventive approach to reduce stroke risk in AF via risk‑based anticoagulation
How it is given or performed
NOAC selected by treating physician at standard oral dosing throughout follow‑up
No anticoagulant treatment administered during follow‑up
Oral anticoagulants prescribed based on CHA2DS2‑VASc assessed stroke risk
Evidence status
Efficacy for preventing stroke/systemic embolism in AFOTS remains unestablished until trial results are available
Natural history without anticoagulation under study; efficacy not assessed
Randomized evidence supports stroke risk reduction with oral anticoagulation in chronic AF but not specifically for POAF after noncardiac stress events
Important risks
Risk of bleeding associated with NOAC use
No bleeding risk but potential for thromboembolic events unmitigated
Recognized bleeding risk balanced against stroke prevention based on stroke risk
Important limitations
Efficacy and safety in the specific AFOTS population are not yet known
Absence of anticoagulation may leave stroke risk unchecked; control arm lacks intervention
Evidence guiding anticoagulation specifically after transient stress‑related AF is limited and not directly addressed in guidelines
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 55Years +
All Genders
Eligibility Criteria
You may qualify if you...
Have had at least one episode of clinically important atrial fibrillation occurring transiently with stress (AFOTS) during one of these: noncardiac surgery in the past 35 days with overnight hospital stay, noncardiac day surgery causing enough stress to cause AFOTS, or acute medical illness requiring hospital admission in the past 35 days causing AFOTS
Be in normal sinus rhythm at the time of randomization
Meet one of these high-risk criteria: age 55-64 years with known cardiovascular disease, recent major vascular surgery, CHA2DS2VASc score of 3 or higher, or elevated postoperative troponin; age 65-74 years with known cardiovascular disease, recent major vascular surgery, CHA2DS2VASc score of 2 or higher, or elevated troponin; or age 75 years or older
Provide written informed consent
You will not qualify if you...
Cardiac diagnosis as the primary reason for hospital admission
History of documented chronic atrial fibrillation before noncardiac surgery
Need for long-term systemic anticoagulation
Ongoing need for long-term dual antiplatelet treatment
Contraindication to oral anticoagulation
Severe renal insufficiency (creatinine clearance less than 20 ml/min)
Severe liver cirrhosis (Child-Pugh Class C)
Acute stroke in the past 14 days
Cardiac surgery in the past 35 days
History of nontraumatic bleeding in brain, eye, or spine
Bleeding disorders or bleeding tendency
Expected non-compliance with follow-up or study medications
Life expectancy less than 1 year due to other disease
Women who are pregnant, breastfeeding, or of childbearing potential not using effective contraception
Previously enrolled in this trial
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Up to 24 months or until final follow-up
Participants are randomized to receive either a non-vitamin K oral anticoagulant (NOAC) or no oral anticoagulation and are followed to assess prevention of stroke and vascular events.
Regular visits over the course of follow-up as determined by the participant's physician
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Similar Trials
Study Evaluating Combined Cognitive and Balance Rehabilitation for Adults Recovering From Stroke
Using 320-Detector CT to Measure Heart Tissue Fibrosis in Adults with Atrial Fibrillation
Before Catheter Ablation Treatment
Using 5T MRI and Metabolomics to Predict Hemorrhage Risk in Moyamoya Disease A Prospective Observational Cohort Study
Testing Caregiver-Assisted Strategy Training to Improve Daily Activities for Adults After Stroke in a Multi-Center Trial
Stroke Recovery Study Using EEG-Guided Muscle and Tongue Stimulation
Evaluating Brain-Computer Interface and Functional Electric Stimulation Therapy
Digital Intervention to Improve Depression and Executive Function After Stroke Using AKL-T01 and Coaching
Smart Home-Based Upper Limb Rehabilitation Using Robot and Task Training for Adults with Stroke and Spinal Cord Injuries
Study of Brain Activity Using Functional Near-Infrared Spectroscopy in Stroke Patients During Mirror Movement
Using a Mobile BrainBody Imaging System to Improve Post-Stroke Walking with a Robotic Device
Study on Intravenous Thrombolysis Using Alteplase or Tenecteplase for Acute Ischemic Stroke Treated Between 4.5 and 24 Hours After Onset
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Detection and management of postoperative atrial fibrillation after coronary artery bypass grafting or non-cardiac surgery: a survey by the AF-SCREEN International Collaboration.
Giuseppe Boriani, Jacopo F Imberti, William F McIntyre...